RGC

$22.97

Market ClosedAs of Mar 17, 8:00 PM UTC

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Motley Fool
Mar 7, 2026

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 6, 2026

A Look At Regencell Bioscience Holdings (RGC) Valuation After Department Of Justice Investigation News

Regencell Bioscience Holdings (NasdaqCM:RGC) is under investigation by the U.S. Department of Justice over trading in its ordinary shares and various corporate, financial, and accounting matters, placing legal risk firmly in focus for investors. See our latest analysis for Regencell Bioscience Holdings. The stock has been volatile, with a 1 day share price return of a 4.87% decline and a 7 day decline of 7.91%, yet a 90 day share price return of 49.08%. The 1 year total shareholder return is...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 5, 2026

Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag

Regencell Bioscience is working on TCM opportunities, but what exactly is TCM?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 1, 2026

Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need

Don't follow general market sentiment when it comes to these two stocks.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
24/7 Wall St.
Feb 19, 2026

These 3 Growth Stocks Won’t Be This Cheap Forever

Finding top growth stocks with the kind of capital appreciation upside long-term investors are seeking is the name of the game for a solid majority of investors in the market right now. Indeed, given the returns investors have gotten used to in recent years, outperforming the market has become a game for many. I’m guilty ... These 3 Growth Stocks Won’t Be This Cheap Forever

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.